ConductScience.org, home

Paper40735995

Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.

Lin Q and 7 others. Curr Drug Deliv, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics. Papers, record 40735995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40735995

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.
PubMed
Journal
Curr Drug Deliv
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-09-08
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lin QQixiong
2Wen YYanyan
3Peng YYueyou
4Shi TTianfeng
5Liu KKunkun
6Yu QQiufeng
7Tian WWei
8Meng YYanfeng

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
SorafenibMajor topic
Carcinoma, HepatocellularMajor topic
Polylactic Acid-Polyglycolic Acid CopolymerMajor topic
Liver NeoplasmsMajor topic
Antineoplastic AgentsMajor topic
Humans
Theranostic Nanomedicine
Drug Liberation
Cell Line, Tumor
Cell Survival
Drug Carriers
Nanoparticles

Source PubMed

Download CSV of topics

References77

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
236208844Global burden of primary liver cancer in 2020 and predictions to 2040.J Hepatol2022https://conductscience.org/library/papers/36208844PubMed
338572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
435989535The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.Hepatology2023https://conductscience.org/library/papers/35989535PubMed
537390855Diagnosis and monitoring of hepatocellular carcinoma in Hepatitis C virus patients using attenuated total reflection Fourier transform infrared spectroscopy.Photodiagnosis Photodyn Ther2023https://conductscience.org/library/papers/37390855PubMed
639095799Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma.Diagn Pathol2024https://conductscience.org/library/papers/39095799PubMed
733541087Epidemiology, mutational landscape and staging of hepatocellular carcinoma.Chin Clin Oncol2021https://conductscience.org/library/papers/33541087PubMed
838808046Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment.Sisli Etfal Hastan Tip Bul2024https://conductscience.org/library/papers/38808046PubMed
938149129A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma.Cureus2023https://conductscience.org/library/papers/38149129PubMed
1034735916Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.Int Immunopharmacol2021https://conductscience.org/library/papers/34735916PubMed
1135719048Research progress of gut microbiota in hepatocellular carcinoma.J Clin Lab Anal2022https://conductscience.org/library/papers/35719048PubMed
1235126844Targets of immunotherapy for hepatocellular carcinoma: An update.World J Hepatol2022https://conductscience.org/library/papers/35126844PubMed
1338195693New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma.Acta Pharmacol Sin2024https://conductscience.org/library/papers/38195693PubMed
1436729264Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.Cancer Metastasis Rev2023https://conductscience.org/library/papers/36729264PubMed
1538760445The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.Br J Cancer2024https://conductscience.org/library/papers/38760445PubMed
1632549224Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.Cancers (Basel)2020https://conductscience.org/library/papers/32549224PubMed
1734291704Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms.J Chemother2022https://conductscience.org/library/papers/34291704PubMed
1839920399Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening.Arch Pharm Res2025https://conductscience.org/library/papers/39920399PubMed
1936457288Aptamer-mediated hollow MnO2 for targeting the delivery of sorafenib.Drug Deliv2023https://conductscience.org/library/papers/36457288PubMed
2038250308Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma.J Hepatocell Carcinoma2024https://conductscience.org/library/papers/38250308PubMed

See all 77 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42245685Nanomaterial-based strategies to overcome sorafenib resistance in hepatocellular carcinoma: from mechanistic insights to translational applications.Front Oncol2026https://conductscience.org/library/papers/42245685PubMed
41578333Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.J Nanobiotechnology2026https://conductscience.org/library/papers/41578333PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40735995

GET https://conductscience.org/api/papers/v1/40735995/references?page=2